I keep getting a blank page when attempting to follow that link.

Am I doing something wrong?

The topic of dosing, when brought up to Matt Pfeffer was met with a "Uhh, err", I'm trying to remember what presentation it was, but now I know why.

It appears that concerns surrounding the reduction of TI used for the Gen 2 from the Medtone inhaler is a legitimate question, and this study attempts to solve it.

The question is:

1. Did the dosing issue affect the current pivotal trials?

2. Will advancing to Phase II / III for dosing of the Gen 2 device, be required, for full launch of Afrezza? Will severe label restrictions be put in place prior to a full Phase III study regarding dosing?